According to a meta-analysis of serum adiponectin from patients with NAFLD, which analyzed 27 studies with a total of 2,243 participants (including 698 controls and 1,545 patients), a higher serum adiponectin concentration was observed in controls compared to patients with NAFLD and NASH. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.